Kumquat Biosciences is identifying small molecules that can be used to treat cancer by stimulating tumor-specific immune responses. By bringing together an accomplished team and distinguished scientific founder with a proven track record of innovative oncology drug development, Kumquat is focusing on translating breakthrough science into first-in-class therapeutics. Currently, Kumquat is using their immuno-oncology platform to discover new clinical candidates and is collaborating with Eli Lilly to progress toward commercialization.

Kumquat Biosciences

Corporate Counsel

Director – Exec Director of Clinical Development

***** ******* *******

Director, Clinical Pharmacology


						
					

Uncategorized

Kumquat Biosciences and Takeda Enter into Strategic Collaboration and Exclusive Global License Agreement to Advance Novel Oral Immuno-Oncology Drug Candidate - PR Newswire

Takeda inks sweet $1.2B-plus deal with Kumquat for immuno-oncology program - Fierce Biotech

See Open Positions

News

 Kumquat Biosciences and Takeda Enter into Strategic Collaboration and Exclusive Global License Agreement to ... 

 Kumquat Biosciences' $1.2 Billion Collaboration and License Agreement with Takeda – Global Legal Chronicle 

 Kumquat Biosciences divulges new SOS1/GTPase KRAS interaction inhibitors 

Fierce Pharma Asia—Leqembi's cost to Medicare; Takeda's $1.2B-plus Kumquat deal; Fujifilm Diosynth's reorg - FiercePharma

 Kumquat Biosciences discovers new GTPase KRAS mutant inhibitors for cancer 

Kumquat Biosciences patents PTPN1 and PTPN2 inhibitors for treatment of cancer - BioWorld Online

Eli Lilly bets $70M upfront and another $2B in biobucks for Kumquat's immuno-oncology small molecules - Fierce Biotech

 Takeda inks sweet $1.2B-plus immuno-oncology deal with Kumquat 

Contact

 Heterocyclic compounds and uses thereof 

Kumquat Biosciences and Takeda Enter into Strategic Collaboration and Exclusive Global License Agreement to Advance Novel Oral Immuno-Oncology Drug Candidate

 Takeda and Kumquat Biosciences for immuno-oncology deal | G&E Partners posted on the topic 

Takeda gains rights to Kumquat’s immune-oncology programme in deal worth over $1.2bn - PMLiVE

July 2021

 Benzo-fused n-heterocycles and uses thereof 

 Kumquat Biosciences presents new SOS1 inhibitors 

 Compositions and methods for potentiating immune response 

Lilly seeks fruit from Kumquat I-O platform in potential $2B+ deal - BioWorld Online

 Modulators of cell proliferation and uses thereof 

Kumquat Biosciences discovers new GTPase KRAS mutant inhibitors for cancer - BioWorld Online

 Chart of the Day: Eli Lilly - A Retail Investor Favorite 

Culture

 Fused heteroaryl compounds useful as anticancer agents 

 Compositions and methods for potentiating immune activity 

Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses - Investors | Eli Lilly and Company

 Lilly seeks fruit from Kumquat I-O platform in potential $2B+ deal 

 Kumquat Biosciences patents new SOS1/KRAS interaction inhibitors 

Kumquat Biosciences describes new GTPase KRAS inhibitors for cancer - BioWorld MedTech

April 16, 2024

The Lilly and the Kumquat - The Medicine Maker

 Macrocyclic heterocycles and uses thereof 

PTPN1 and PTPN2 inhibitors reported in Nerio Therapeutics patent - BioWorld MedTech

 Kumquat Biosciences describes new GTPase KRAS inhibitors for cancer 

July 29, 2021

Kumquat Biosciences - The Pharma Letter

April 2024

Pipeline

 Kumquat Biosciences patents PTPN1 and PTPN2 inhibitors for treatment of cancer 

Prosetta Biosciences discovers new quinazoline compounds - BioWorld MedTech

Wilson Sonsini Advises Kumquat Biosciences’ $1.2B Strategic Collaboration with Takeda - Wilson Sonsini

 Chart Of The Day: Eli Lilly - Big Profits In Big Pharma 

Kumquat Biosciences divulges new SOS1/GTPase KRAS interaction inhibitors - BioWorld Online

 Lilly signs deal with Kumquat Biosciences 

Kumquat Biosciences

Business:

About: